{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-24-000009","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.303836+00:00","generated_at":"2026-06-05T22:39:36.879095+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NeoGenomics Q4 revenue $156M (+12% YoY); FY loss narrows 39% to $88M; guides FY24 rev $650-660M","bullets":["Q4 consolidated revenue $156M (+12% YoY); Clinical Services +20% to $130M, Advanced Diagnostics -17% to $25M.","Q4 net loss $14M (improved from $23M loss in Q4'22); Adjusted EBITDA turned positive to $9M (vs -$1M).","Full year revenue $592M (+16% YoY); net loss $88M (improved from $144M); Adjusted EBITDA positive $3M (vs -$48M).","FY2024 guidance: revenue $650-660M (10-12% growth), net loss $(72)-$66M, Adjusted EBITDA $21-24M (600-700% improvement).","Cash and marketable securities $415M at year-end; no debt or dividend changes reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-24-000009","json":"https://secwatch.observer/filing/0001077183-24-000009.json","markdown":"https://secwatch.observer/filing/0001077183-24-000009.md","text":"https://secwatch.observer/filing/0001077183-24-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000009/0001077183-24-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000009/neo-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:39:36.879095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14fa3ff921c063145d653dec26887c93d053d4ad","claim":"NEOGENOMICS INC reported fourth fiscal quarter of 2023 and full year ended December 31, 2023 results: revenue $156 million, net income $14 million. Guidance initiated.","evidence_excerpt":"forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- NeoGenomics Reports Fourth Quarter and Full Year 2023 Results Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million Fort Myers, Florida, (February 20, 2024) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”) , a leading provider of oncology","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000009/0001077183-24-000009-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth fiscal quarter of 2023 and full year ended December 31, 2023"},{"label":"Revenue","value":"$156 million"},{"label":"Net income","value":"$14 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}